Literature DB >> 31258797

EVALUATION OF CARDIOVASCULAR RISK AND MYOCARDIAL PERFUSION IN PATIENTS WITH RADICALLY TREATED DIFFERENTIATED THYROID CARCINOMA AND REPEATED EPISODES OF IATROGENIC HYPOTHYROIDISM.

M Saftencu1, E Barbus1,2, C Pestean1,2, A Piciu1,2, D Piciu1,2.   

Abstract

CONTEXT: Patients with radically treated differentiated thyroid carcinoma (DTC) undergo multiple episodes of iatrogenously-acquired hypothyroidism for the oncological follow-up. In some patients, this elevates high-sensitive C-reactive protein (hsCRP), a cardiovascular risk biomarker.
OBJECTIVE: We wanted to determine if there is any correlation between repeated hypothyroidism episodes, elevated hsCRP and an increased cardiovascular risk as stated through myocardial perfusion.
DESIGN: Between July 2014-January 2015, we analyzed serological levels of hsCRP for identifying our patients' cardiovascular risk; we performed a myocardial perfusion scintigraphy to observe the alterations. SUBJECTS AND METHODS: We included 27 patients (n=27), mean age of 52±10: CI (95%),14 female, all disease- free after thyroidectomy, radioiodine ablation and chronic thyroid hormone treatment. We assigned the cardiovascular risk category for each patient according to hsCRP levels; all patients underwent a myocardial perfusion scintigraphy in order to determine the cardiac perfusion index (CPI).
RESULTS: hsCRP has been higher in > 65 years old male patients with more than 5 thyroid hormone withholdings. hsCRP is significantly associated with CPI (p=0.001). Spearman's rank correlation indicates a strongly positive linear correlation between these two parameters (r=0.745).
CONCLUSIONS: Repeated thyroid hormonal withdrawals in patients with DTC during the long-term follow-up elevated hsCRP at cardiovascular risk levels, having an impact on myocardial perfusion.

Entities:  

Keywords:  cardiovascular risk; differentiated thyroid carcinoma; hsCRP; myocardial perfusion; thyroid hormone withdrawal

Year:  2016        PMID: 31258797      PMCID: PMC6586750          DOI: 10.4183/aeb.2016.30

Source DB:  PubMed          Journal:  Acta Endocrinol (Buchar)        ISSN: 1841-0987            Impact factor:   0.877


  25 in total

1.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association.

Authors:  Thomas A Pearson; George A Mensah; R Wayne Alexander; Jeffrey L Anderson; Richard O Cannon; Michael Criqui; Yazid Y Fadl; Stephen P Fortmann; Yuling Hong; Gary L Myers; Nader Rifai; Sidney C Smith; Kathryn Taubert; Russell P Tracy; Frank Vinicor
Journal:  Circulation       Date:  2003-01-28       Impact factor: 29.690

Review 2.  Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma.

Authors:  Ian D Hay
Journal:  J Surg Oncol       Date:  2006-12-15       Impact factor: 3.454

3.  Procedure guideline for myocardial perfusion imaging 3.3.

Authors:  H William Strauss; D Douglas Miller; Mark D Wittry; Manuel D Cerqueira; Ernest V Garcia; Abdulmassi S Iskandrian; Heinrich R Schelbert; Frans J Wackers; Helena R Balon; Otto Lang; Josef Machac
Journal:  J Nucl Med Technol       Date:  2008-08-14

4.  The HiLo trial: a multicentre randomised trial of high- versus low-dose radioiodine, with or without recombinant human thyroid stimulating hormone, for remnant ablation after surgery for differentiated thyroid cancer.

Authors:  U Mallick; C Harmer; A Hackshaw
Journal:  Clin Oncol (R Coll Radiol)       Date:  2008-06       Impact factor: 4.126

5.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

6.  Highly-sensitive C-reactive protein, a biomarker of cardiovascular disease risk, in radically-treated differentiated thyroid carcinoma patients after repeated thyroid hormone withholding.

Authors:  A Piciu; D Piciu; R J Marlowe; A Irimie
Journal:  Exp Clin Endocrinol Diabetes       Date:  2013-02-20       Impact factor: 2.949

7.  Thyroid cancer incidence 25 years after Chernobyl, in a Romanian cancer center: is it a public health problem?

Authors:  Doina Piciu
Journal:  Curr Radiopharm       Date:  2013-12

8.  Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients.

Authors:  M Chianelli; V Todino; F M Graziano; C Panunzi; D Pace; R Guglielmi; A Signore; E Papini
Journal:  Eur J Endocrinol       Date:  2008-12-12       Impact factor: 6.664

9.  Guidelines for radioiodine therapy of differentiated thyroid cancer.

Authors:  M Luster; S E Clarke; M Dietlein; M Lassmann; P Lind; W J G Oyen; J Tennvall; E Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10       Impact factor: 9.236

10.  Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal.

Authors:  R Elisei; M Schlumberger; A Driedger; C Reiners; R T Kloos; S I Sherman; B Haugen; C Corone; E Molinaro; L Grasso; S Leboulleux; I Rachinsky; M Luster; M Lassmann; N L Busaidy; R L Wahl; F Pacini; S Y Cho; J Magner; A Pinchera; P W Ladenson
Journal:  J Clin Endocrinol Metab       Date:  2009-10-22       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.